Tempsens Instruments (India) IPO Day 3: GMP ₹270 (+₹55)
Here we are, folks, on Day 3 of the Tempsens Instruments (India) IPO, and the heat is definitely on! The IPO, which opened its subscription window on August 20, 2026, and is set to close on August 24, 2026, is starting to show some interesting trends. With an issue price fixed at ₹300 per share, investors have been keeping a close eye on how this mainboard IPO on the NSE is performing. Let’s dive into the latest updates and see what the numbers are telling us.
| Date | GMP | Est. Listing |
|---|---|---|
| 22 Aug | +₹285 | ₹585 |
| 21 Aug | +₹270 | ₹570 |
| 20 Aug | +₹215 | ₹515 |
| 19 Aug | +₹170 | ₹470 |
| 18 Aug | +₹150 | ₹450 |
Subscription Status
As of Day 3, the subscription numbers for Tempsens Instruments are looking… well, they’re looking like they’re just getting started! Currently, the subscription figures for Retail, NII (Non-Institutional Investors), and QIB (Qualified Institutional Buyers) are all at 0x. This isn’t necessarily a cause for alarm just yet, especially on Day 3. Often, the bulk of subscriptions, particularly from institutional investors, comes in during the last couple of days of the IPO period. However, it’s something to monitor closely as we move into the final stretch. The low numbers so far could indicate cautiousness or simply that the big players haven’t made their move. We’ll be watching to see if the retail segment picks up any steam, as their participation is often an early indicator of market sentiment.
For context, the lot size for this IPO is 50 shares. This means retail investors need to apply for at least one lot, and the total application amount for a single lot is ₹15,000 (50 shares * ₹300 issue price). The absence of any significant subscription across all categories at this stage is quite peculiar. It could mean that many potential investors are waiting for a clearer picture, or perhaps the initial marketing push hasn’t fully translated into applications yet. The bottom line is, while zero subscriptions aren’t ideal, it’s not uncommon for IPOs to see a surge in demand towards the end.
| Category | Subscription | Progress |
|---|---|---|
| Retail | 61.00x | |
| NII / HNI | 314.44x | |
| QIB | 302.88x | |
| Total | 314.44x |
GMP Update
Now, let’s talk about the Grey Market Premium (GMP). This is where things get a bit more exciting! The current GMP for Tempsens Instruments is standing strong at ₹270. This is a significant jump from yesterday’s GMP of ₹215, marking an increase of ₹55. This upward movement in GMP is a very positive sign for the IPO. It suggests that the grey market is anticipating a strong listing performance for the company.
A GMP of ₹270 on an issue price of ₹300 implies an expected listing price of around ₹570 (Issue Price + GMP). This is a substantial premium and certainly makes the IPO look attractive from a listing gains perspective. The consistent increase in GMP over the past few days, and especially the jump today, indicates growing investor interest and confidence in Tempsens Instruments. This is encouraging news for those who are considering applying.
Should You Apply?
So, the million-dollar question: should you be putting your money into the Tempsens Instruments IPO? Based on the data we have today, it’s a mixed bag, but leaning towards optimistic. The subscription numbers are currently non-existent, which is a point of caution. You’d ideally want to see some traction by Day 3. However, the GMP is incredibly strong and showing a healthy upward trend. A GMP of ₹270, pointing towards a listing price of ₹570, is a compelling proposition.
Remember, the SEBI advisor guidelines always emphasize thorough due diligence. While the GMP is a good indicator of market sentiment, it’s not a guarantee. You’ll want to look at the company’s fundamentals, its business prospects, and the overall market conditions. That said, the strong GMP suggests that the market has a positive outlook on Tempsens Instruments. If you’re looking for potential listing gains and are comfortable with the associated risks, this IPO might be worth considering, especially given the robust GMP. However, always do your own research before making any investment decisions.